Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
SAFE Drugs Act of 2025
Client: COLLABORATIVE FOR EVIDENCE-BASED MEDICINES · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Drug compounding issues; SAFE Drugs Act (H.R. 6509 / S. 3794)
SAFE Drugs Act of 2026
Client: COLLABORATIVE FOR EVIDENCE-BASED MEDICINES · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Drug compounding issues; SAFE Drugs Act (H.R. 6509 / S. 3794)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
COLLABORATIVE FOR EVIDENCE-BASED MEDICINES via FAEGRE DRINKER BIDDLE & REATH LLP
2026 · third_quarter · RR
Drug compounding issues; SAFE Drugs Act (H.R. 6509 / S. 3794)
Source: Senate LDA